Cardio Diagnostics Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Cardio Diagnostics Holdings, Inc. reported a reduced net loss in 2025 compared to 2024, despite a decline in revenue, as it continues to focus on commercializing its AI-driven cardiovascular diagnostic tests and expanding market reach.
NASDAQ
Cardio Diagnostics Holdings, Inc. reports a slight increase in revenue for 2024 while navigating evolving FDA regulations for laboratory developed tests.
NASDAQ
10-K: Cardio Diagnostics Holdings, Inc. Details Capital Structure and Regulatory Landscape in 10-K Filing
Cardio Diagnostics Holdings, Inc. outlines its capital stock, warrants, and regulatory environment in its annual 10-K filing, highlighting its focus on cardiovascular disease diagnostics.